Keros Therapeutics (KROS) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rocket Pharmaceuticals (RCKT) has outperformed Keros Therapeutics (KROS) over the past year, losing 33.4% versus a loss of 36.3%. Over five years, KROS leads with a -80.2% price change compared with -91.8% for RCKT. Rocket Pharmaceuticals is the larger company by market cap ($217.7 million vs $217.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | RCKT |
|---|---|---|
| Share price | $11.08 | $1.95 |
| Market cap | $217.44M | $217.74M |
| 1-day change | -2.72% | -7.58% |
| YTD return | -45.58% | -44.44% |
| 1-year return | -36.29% | -33.45% |
| 5-year return | -80.25% | -91.76% |
| EPS (TTM) | $-2.32 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $243.86M | $0 |
| Net income (latest FY) | $87.01M | $-223.12M |
| Operating margin | 27.71% | — |
| Net margin | 35.68% | — |
| 52-week high | $22.55 | $5.45 |
| 52-week low | $8.98 | $1.94 |
| Distance from 52-week high | -50.86% | -64.22% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +78.97% | +326.15% |
| Average volume | 196.50K | 1.90M |
| Shares outstanding | 19.62M | 111.66M |
| Employees | 87 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
KROS vs RCKT FAQ
Which is bigger, Keros Therapeutics or Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) is larger, with a market capitalization of $217.74M compared with $217.44M for Keros Therapeutics (KROS).
Which stock has performed better over the past year, KROS or RCKT?
RCKT returned -33.45% over the past 12 months, compared with -36.29% for KROS (price return, excluding dividends). Past performance does not predict future results.
Are Keros Therapeutics and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.